DFY.TO 0.66AGF.B.TO 0.05CDR.TO 0.33BLX -0.69KINS 0.34MCY -1.24DIS -0.06ATD.TO 0.6
Johnson & Johnson (JNJ)

NYSE:JNJ

Johnson & Johnson (JNJ)

253.04
+3.07 (1.23%)
as of Jul 17, 2026, 8:00:00 pm Market Open.
697 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 19, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a mix of challenges and opportunities, as reflected in various expert reviews. Despite a downturn attributed to disappointing performance in the cardio segment, analysts maintain a generally positive outlook due to a strong core pharmaceutical business and an impressive lineup of drugs in their pipeline. With the recent spin-off of its orthopedics division, JNJ is now more focused on high-margin pharmaceuticals and medical devices, areas poised for substantial growth. Legal troubles related to talcum powder lawsuits appear to be diminishing, further alleviating concerns surrounding the company's stock. Overall, JNJ is seen as a solid investment for long-term growth, particularly in the backdrop of the upcoming earnings report, where strong performance is anticipated in oncology and orthopedics.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
PG
DON'T BUY

Johnson & Johnson(JNJ)

Jan 02, 2002
A bit expensive, but a good hold. Buy near $50.
Photo of Brad WillockBrad WillockUnlock Rating
$58.70

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Johnson & Johnson(JNJ)

Dec 28, 2001
Had a nice run. Probably near its top.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$59.86

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Johnson & Johnson(JNJ)

Dec 27, 2001
Fair Market Value = $78. Could break through. Caution.
Photo of Ross HealyRoss HealyUnlock Rating
$60.02

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Johnson & Johnson(JNJ)

Dec 10, 2001
Investors are moving out of these defensive stocks.
Photo of John ZechnerJohn ZechnerUnlock Rating
$55.52

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Johnson & Johnson(JNJ)

Oct 16, 2001
Good numbers report today. Expects stock to move sideways for next few quarters.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$56.77

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Johnson & Johnson(JNJ)

Sep 10, 2001
Getting a little rich. Good company. A good buy and hold. 15% earnings growth.
Photo of Brad WillockBrad WillockUnlock Rating
$55.62

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Johnson & Johnson(JNJ)

Aug 23, 2001
Good company. Reliable earnings. Slow, but consistent growth.
Photo of Brendan KyneBrendan KyneUnlock Rating
$54.64

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Johnson & Johnson(JNJ)

Aug 14, 2001
Good sector to be in.
Photo of Neil MurdockNeil MurdockUnlock Rating
$56.99

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Johnson & Johnson(JNJ)

Jun 12, 2001
Solid company. 1.4% yield. Conservative.
Photo of Jeff MorrisonJeff MorrisonUnlock Rating
$101.80

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Johnson & Johnson(JNJ)

Apr 10, 2001
High quality. 10/15% growth each year.
Photo of Jeff MorrisonJeff MorrisonUnlock Rating
$92.03

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Johnson & Johnson(JNJ)

Apr 04, 2001
Good pipeline. Good defensive play.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$86.91

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Johnson & Johnson(JNJ)

Mar 14, 2001
Better diversified than a lot of pharmaceuticals
Photo of Phil SmithPhil SmithUnlock Rating
$93.25

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Johnson & Johnson(JNJ)

Oct 30, 2000
A no brainer. Consistent growth
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$94.00

Stock price when the opinion was issued

$251.98

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
Showing 616 to 628 of 628 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX -5.4$68.95
RIO -0.52$90.15
MAR -4.9$366.24
META -18.53$646.01
AMT 1.14$170.06

Today's Top Picks

DFY.TO 0.66$78.28
AGF.B.TO 0.05$22.89
CDR.TO 0.33$3.91
BLX -0.69$59.25
KINS 0.34$20.09

Popular Articles

Latest Sell Signals

NFLX -5.4$68.95
NFLX -5.4$68.95
CAT 3.11$880.28
NFLX -5.4$68.95
DOL.TO 1.92$190.87

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bruce Campbell (2)

Bruce Campbell (2)

Stone Castle Investment Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like